What it is
BPC-157 is a synthetic 15-amino-acid pentadecapeptide (sequence GEPPPGKPADDAGLV, MW 1,419.54 Da, CAS 137525-51-0, PubChem CID 9941957) derived from a partial sequence of a protective protein found in human gastric juice. It was first isolated by Predrag Sikiric and colleagues at the University of Zagreb in 1993. Three consecutive proline residues at positions 3–5 give the molecule unusual stability — it remains intact in human gastric juice for over 24 hours and resists most peptidases (Sikiric 2024). This stability has enabled investigation of oral administration in animal models, distinguishing BPC-157 from most bioactive peptides that require parenteral delivery. Despite three decades of preclinical research, no major regulatory agency has approved it for human use.
How it works
- 01
Modulation of the nitric oxide (NO) system
BPC-157 exerts vasoactive and cytoprotective effects through the nitric oxide system. Hsieh (2020, Scientific Reports) elucidated a Src–Caveolin-1–eNOS signaling cascade: BPC-157 phosphorylates Src kinase, which phosphorylates Cav-1, releasing eNOS from inhibitory binding and increasing NO production. Notably, the effect is bidirectional — BPC-157 counteracts both L-NAME-induced hypertension and L-arginine-induced hypotension, behaving as a homeostatic NO-system modulator rather than a pure agonist or antagonist.
- 02
VEGFR2 activation and angiogenesis
Hsieh (2017, J Mol Med) demonstrated that BPC-157 upregulates vascular endothelial growth factor receptor 2 (VEGFR2) at both mRNA and protein levels in endothelial cells, promotes VEGFR2 internalization (blocked by the endocytosis inhibitor dynasore), and activates the downstream Akt–eNOS cascade. This drives the consistent angiogenic effect observed at injury sites in animal models — and underlies BPC-157's interest in tissue repair, ischemia recovery, and collateral-vessel formation in vascular occlusion models.
- 03
FAK–paxillin pathway and tendon fibroblast migration
Chang (2011, J Appl Physiol) showed dose-dependent activation of focal adhesion kinase (FAK) and paxillin in tendon fibroblasts: enhanced expression and phosphorylation, increased fibroblast migration in transwell assays, F-actin cytoskeletal remodeling, and preserved viability under H₂O₂ oxidative stress. This is the proposed mechanism for the consistent tendon-healing effect in animal models. McGuire (2025) flags the same FAK-paxillin pathway as relevant in cancer cell biology — a theoretical safety question that remains untested in humans.
- 04
Growth hormone receptor upregulation
Lovric-Bencic (2018, Molecules) showed that BPC-157 increases growth hormone receptor (GHR) expression in tendon fibroblasts in a dose- and time-dependent manner, enhances GH sensitivity, and activates JAK2 phosphorylation. This provides a mechanism by which BPC-157 could amplify endogenous GH/IGF-1 axis signaling in damaged tissue without requiring exogenous GH administration.
- 05
Cytoprotection and stress-response upregulation
Sikiric (2020, Gut and Liver) reviewed BPC-157's broader cytoprotective signature: upregulation of heat shock proteins (HSPs) and heme oxygenase-1 (HO-1), reduction of pro-inflammatory cytokines, mitochondrial preservation, and organoprotection extending across stomach, intestine, liver, pancreas, heart, and brain. Sikiric (2024, Pharmaceuticals) added neurotransmitter-system modulation — restoration of dopaminergic, serotonergic, GABAergic, and glutamatergic balance after experimental stress — which underlies the CNS-recovery findings (stroke, TBI, spinal cord injury) reviewed by Vukojevic (2022).
- 06
What is NOT known about the mechanism
No specific molecular receptor for BPC-157 has been identified. The pleiotropic effects across tissues are inferred from downstream pathway activation rather than receptor pharmacology. Pharmacokinetics in humans are essentially undocumented in peer-reviewed literature: animal data shows hepatic metabolism with a sub-30-minute plasma half-life and renal clearance, but human PK has not been formally characterized. This receptor-and-PK gap is a major reason the evidence grade is not higher despite the depth of mechanistic work.